Remove Medicaid Remove Medicare Remove Peripheral Arterial Disease
article thumbnail

Elixir Medical Granted FDA Breakthrough Device Designation for DynamX Bioadaptor

DAIC

We look forward to working with FDA, Centers for Medicare & Medicaid Services, and respective physician societies to bring this technology t­­o U.S. patients as soon as possible to elevate the standard of care for cardiovascular disease treatment.”

article thumbnail

R3 Vascular Receives WGC IRB Approval for its ELITE-BTK Pivotal Trial of its Next Generation Bioresorbable Scaffold

DAIC

a medical device company dedicated totreating peripheral arterial disease (PAD), recently announceit received WCG Institutional Review Board (IRB) approval for the ELITE-BTK Pivotal Trial of its MAGNITUDEDrug Eluting Next Generation Bioresorbable Scaffold for Below-the-Knee Peripheral Arterial Disease (PAD).